Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
September 27th, 2019
12.9K views
Typically, the mouse neck injection model is used for evaluate pruritogen-induced scratch behaviors. However, the model provides information only on itch, not pain. Here, a cheek injection model is introduced in mice which can be used to simultaneously measure pain and itch-related behaviors.
Overview
This study introduces a novel cheek injection model in mice to simultaneously measure pain and itch-related behaviors, addressing limitations of traditional models that focus solely on itch. The research provides insights into the interactions between pain and itch sensations, showing distinct behavioral responses between the two.
Key Study Components
Area of Science
- Neuroscience
- Behavioral analysis
- Pain and itch mechanisms
Background
- Existing mouse neck injection models assess pruritogen-induced scratch behaviors but do not evaluate pain.
- The cheek injection model allows for the concurrent analysis of pain and itch.
- The method establishes a clearer distinction between itch and pain-related behaviors.
- Applications of different substances offer insights into pain and itch responses.
Purpose of Study
- Introduce a method for simultaneous measurement of pain and itch.
- Evaluate the effectiveness of algogens and pruritogens on mouse behaviors.
- Provide detailed methodology for training peers in behavioral analysis.
Methods Used
- The main platform involves video recording mouse behaviors during injection experiments.
- Mice receive intradermal injections of test substances in the cheek or neck.
- Key steps include acclimatization, shaving of fur, and multi-behavioral observation.
- Data is recorded for 30 minutes post-injection to analyze scratching, wiping, and grooming behaviors.
Main Results
- Algogens were found to reduce scratching behaviors, while capsaicin's effect on scratching remains unclear.
- The cheek injection model allowed distinct observation of itch (scratching) and pain (wiping) behaviors.
- Histamine induced significant scratching, demonstrating receptor-mediated behaviors.
- The application of anti-histamine inhibited scratching, confirming the role of histamine in itch sensation.
Conclusions
- The study validates an innovative model for concurrent evaluation of itch and pain sensations in research.
- This method enhances understanding of the distinct mechanisms underlying itch and pain responses.
- Ultimately, the findings may inform therapeutic approaches for managing pain and itch in clinical settings.
Frequently Asked Questions
What are the advantages of the cheek injection model?
The cheek injection model allows for simultaneous measurement of pain and itch, providing a more comprehensive understanding of these sensations compared to traditional methods.
How is the cheek injection method implemented?
Mice are acclimatized in recording cages, and after shaving, a test substance is injected into the shaved cheek. Mouse behaviors are recorded for analysis.
What types of behaviors are observed in this study?
Key behaviors include scratching, which correlates with itch perception, and wiping behaviors, which are related to pain sensation.
How can this model be adapted for other studies?
The cheek injection model can be adapted by changing the type of test substances and varying the experimental conditions for specific research questions regarding pain and itch.
What are the limitations of the study?
Challenges include mastering the discrimination between different behaviors like scratching and grooming, which may require practice and careful observation.
Executive Industry Relevance
Distinguishing pain from itch in preclinical models remains a critical challenge in target validation for dermatological and neurological therapeutics. The cheek injection model enables concurrent, behaviorally distinct measurement of pruritic and algogenic responses, improving mechanistic de-risking in early discovery. This supports more confident go/no-go decisions by reducing false positives in phenotypic screening campaigns.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by isolating itch-specific versus pain-related behavioral outputs.
- Operational Value: Provides a standardized assay to differentiate pruritogens from algogens using scratching and wiping as discrete readouts.
- Predictive Value: Increases confidence in target selection by confirming pruritic action in a system that mirrors human sensory responses, as demonstrated with LPA.
Screening & Assay Development
- Assay Readiness: Generates quantitative, time-resolved behavioral data (scratching bouts, wiping events) suitable for high-content screening.
- Reproducibility: Standardized acclimatization, injection, and video recording protocols reduce inter-experiment variability.
- Scalability: Compatible with multi-cage setups and automated video analysis for increased throughput in lead identification.
Translational & Preclinical Research
- Disease Relevance: Validated using LPA, a pruritogen in cholestatic patients, showing conserved itch-specific response across species.
- Mechanistic De-risking: Clarifies whether a compound activates itch or pain pathways, reducing ambiguity in target mechanism.
- Translational Continuity: Supports progression from target hit to preclinical candidate by confirming desired sensory profile.
Pipeline & Workflow Integration
The model fits within the discovery continuum from target validation through lead optimization, where distinguishing on-target itch from off-target pain is essential for safety profiling.
- Discovery Biology: Supports hypothesis testing by isolating pruritogenic activity independent of nociceptive confounders.
- Screening: Enables assay standardization with quantifiable outputs (scratch bouts per 30 min) for compound library evaluation.
- Analytics: Facilitates side-by-side comparison of itch and pain behaviors from single injections, improving data interpretability.
- Translational Research: Aligns with biomarker strategies by verifying pruritic action in a system predictive of human response.
- Enterprise Reuse: Establishes a reusable behavioral platform for multiple projects targeting itch or pain pathways.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in sensory neuroscience targets by decoupling itch and pain readouts.
- Operational Value: Enhances reproducibility across sites through standardized shaving, injection, and video-based scoring.
- Strategic Value: Improves portfolio triage by identifying compounds with unwanted pain liability early in discovery.
- Portfolio Impact: Enables risk-adjusted advancement by confirming desired sensory phenotype before preclinical investment.
Implementation Considerations
- Requires training to reliably discriminate scratching, wiping, and grooming behaviors during video analysis.
- Dependent on controlled environmental conditions (temperature, humidity, sound) and consistent video frame rates (30–60 fps).
- Necessitates standardization across teams for shaving protocols, injection volume (10 µL), and post-injection observation duration (30 min).
- Adaptation to different models requires validation that cheek injection preserves distinct itch/pain behavioral separation.
- Limited to observable behaviors; does not capture central neural mechanisms without complementary electrophysiology or imaging.
Biopharma FAQs
Why does distinguishing scratching from wiping matter for target validation?
Scratching reflects itch-related behaviors while wiping indicates pain-related responses in the cheek injection model. This separation allows researchers to confirm whether a compound acts as a pruritogen or algogen, reducing false attribution of mechanism. Accurate behavioral classification supports confident target selection in early discovery.
How does isolating the independent variable (test substance) improve discovery pipeline confidence?
By injecting a single test substance per mouse and measuring distinct behavioral outputs, the model isolates the compound’s effect on itch versus pain pathways. This prevents confounding from mixed stimuli and enables clear dose-response relationships. Such precision strengthens hypothesis testing in target validation campaigns.
What do quantitative dependent variable measurements (scratch bouts, wiping events) enable in assay development?
Counting scratch bouts and wiping events provides objective, quantifiable readouts for comparing compound activity and potency. These metrics support assay standardization, inter-lab reproducibility, and screening throughput. Quantitative data also facilitates structure-activity relationship analysis during lead optimization.
Why are replication requirements important for cross-functional collaboration in behavioral studies?
Replication ensures that observed itch or pain responses are consistent across experiments, operators, and laboratory conditions. Standardized protocols for shaving, injection, and video analysis reduce variability and increase data reliability. This consistency enables toxicology, pharmacology, and medicinal chemistry teams to align on compound progression decisions.
What statistical analysis capabilities are required before implementing the cheek injection model in screening workflows?
Implementing the model requires capacity to analyze count-based behavioral data (e.g., scratch bouts per 30 min) using appropriate statistical tests for group comparisons. Researchers must be able to assess significance, variability, and effect size across treatment and control groups. These capabilities are essential for interpreting screening hits and supporting go/no-go decisions.
